Clinical trials: Antiviral Treatment
Hepatitis C, HIV Infection
Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa
Primary Objective: To evaluate the efficacy (sustained virological response 12 weeks after end-of-treatment [SVR12]) of 12-week course of an interferon-free regimen combining sofosbuvir and weight-dosed ribavirin (genotype 2), or…
- Trial name
- TAC (NCT02405013)
- Testing
- Sofosbuvir, Ribavirin, Ledipasvir
- Where
- 4 sites in Cameroon, Côte d’Ivoire and 1 more
- Volunteers
- 120 people
- Sponsor
- ANRS, Emerging Infectious Diseases
EBV Viremia, CMV Viremia
25BT056: Basket Study of Viral Cytotoxic T Lymphocytes
This study is evaluating the safety and effectiveness of virus-specific cytotoxic T lymphocytes (vCTLs) for treating difficult-to-control viral infections caused by cytomegalovirus (CMV), adenovirus (ADV), Epstein-Barr virus…
- Conditions
- EBV Viremia, CMV Viremia, BK Viremia, Adenovirus
- Trial name
- NCT07873970
- Testing
- Virus-Specific Cytotoxic T Lymphocytes (vCTLs)
- Volunteers
- 35 people
- Sponsor
- Children's Hospital of Philadelphia
Hepatitis C, Transplantation Disease Transmission
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
In this study, subjects that do not have Hepatitis C virus (HCV) will be transplanted with livers or kidneys from donors who do have HCV.
- Trial name
- PRO-ACT: (NCT03619837)
- Testing
- Sofosbuvir/Velpatasvir, Sofosbuvir/Velpatasvir/Voxilaprevir
- Where
- 6 sites in United States
- Volunteers
- 122 people
- Sponsor
- University of California, San Francisco
Covid19
COVID-19 Methylene Blue Antiviral Treatment
This is a pilot study of a single-center, blind, randomized, placebo-controlled, parallel-group study testing for the efficacy and safety of Methylene blue when administered topically as a 0.02% solution for nasopharyngeal and…
- Trial name
- COMBAT (NCT05004805)
- Testing
- Methylene Blue, Saline nasal spray
- Where
- Russia
- Volunteers
- 24 people
- Sponsor
- Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences
HIV Infections
Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection
This trial tests the safety and effectiveness of the early use of combinations of anti-HIV drugs in HIV-infected infants and young children in an effort to block virus growth and preserve normal immune functions.
- Trial name
- NCT00000872
- Testing
- Abacavir sulfate, Nelfinavir mesylate, Nevirapine
- Where
- 12 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Congenital Cytomegalovirus (CMV)
Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance
Congenital cytomegalovirus (CMV) infection is the leading cause of non-genetic neurosensory deafness and affects 0.5 to 1% of births.
- Trial name
- GANCIMVEAR (NCT02606266)
- Testing
- Valganciclovir
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Infections
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
The purpose of this study is to compare the anti-HIV efficacy, safety and effect of serum lipids of two boosted protease inhibitor-based HAART regimens (ARV/RTV v.
- Trial name
- NCT00135395
- Testing
- Atazanavir+ritonavir, Lopinavir+ritonavir
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients
This trial is aimed at studying the antiviral activity, toxicity and pharmacokinetic (PK) interactions of tenofovir DF and atazanavir enhanced with low dose of ritonavir given alone and then concomitantly as part of a salvage…
- Trial name
- NCT00122577
- Testing
- Tenofovir, Atazanavir, Ritonavir
- Where
- France
- Volunteers
- 50 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Intravenous Drug Abuse, Chronic Hepatitis C
Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment
Study objective: Feasibility and efficacy of a standardised psychosocial intervention (psychoeducation) in substituted opioid dependent patients
- Trial name
- Permit (NCT00844272)
- Testing
- Psychoeducation
- Volunteers
- 189 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Virus Diseases
Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza
Danirixin (DNX) is a novel, selective, and reversible antagonist of the C-X-C chemokine receptor (CXCR) 2 and has been shown to decrease neutrophil transmigration and activation to areas of inflammation.
- Trial name
- NCT02927431
- Testing
- Danirixin 15 mg FBE, Danirixin 50 mg FBE, Oseltamivir 75 mg
- Where
- 8 sites in United States, Romania and 2 more
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Influenza
TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD
- Trial name
- NCT00867139
- Testing
- TCAD, Zanamivir or Oseltamivir, Open label treatment with TCAD
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Fred Hutchinson Cancer Center
Alzheimer Disease, Mild Cognitive Impairment
Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease
This study investigates the effects of Valaciclovir treatment to individuals with Alzheimer's disease or Mild Cognitive Impairment of Alzheimer's Disease Type.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Herpes Simplex
- Trial name
- VALZ-Pilot (NCT02997982)
- Testing
- Valaciclovir 500Mg Tablet
- Where
- 2 sites in Sweden
- Volunteers
- 33 people
- Sponsor
- Hugo Lovheim
Herpes Simplex, HIV Infections
An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies
To evaluate the safety and efficacy of intermittent intravenous (IV) foscarnet in the treatment of acyclovir-resistant herpes simplex virus (HSV) infections in AIDS patients and other immunocompromised patients.
- Trial name
- NCT00002021
- Testing
- Foscarnet sodium
- Where
- 2 sites in United States
- Sponsor
- Astra USA
Hepatitis C, Chronic, Mixed Cryoglobulinemia
Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia
Mixed cryoglobulinemia (MC) is common in patients with chronic hepatitis C virus (HCV) infection. Direct-acting antiviral (DAA) regimens are today very effective with sustained virological response rates (SVR12) above 90%.
- Trial name
- NCT03342261
- Testing
- DAA treatment
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Hospices Civils de Lyon
CKD With Hepatitis C
Safety and Efficacy of Sofosbuvir Based Antiviral Regimen for Treating Hepatitis C in Patients With Moderate to Advanced Chronic Kidney Disease and Patients Receiving Renal Replacement Therapy
All patients with chronic kidney disease (stages 3, 4 and 5) and chronic dialysis patients with HCV infection attending nephrology and Hepatology OPD or getting outpatient dialysis at the dialysis unit of ILBS.
- Trial name
- NCT02563665
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Chronic Hepatitis b
Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients
A total of 2000 chronic hepatitis B (CHB) patients with liver biopsy performed at least 1 year after antiviral therapy are enrolled. All the patients will receive original antiviral treatment for the following 10 years.
- Trial name
- NCT03777969
- Where
- 7 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Beijing Friendship Hospital
COVID-19
FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals
The current pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with first presentation of symptoms…
- Trial name
- FLARE (NCT04499677)
- Testing
- Favipiravir, Lopinavir/ Ritonavir
- Where
- 2 sites in United Kingdom
- Volunteers
- 240 people
- Sponsor
- University College, London
Hepatitis B
Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy
The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Positive lymphoma patients treated with rituximab-based immunochemotherapy.
- Trial name
- NCT01768195
- Testing
- Entecavir prophylaxis
- Where
- 13 sites in China
- Volunteers
- 80 people
- Sponsor
- Peking University
HIV Infections
Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults
The primary purpose of the study is to evaluate the antiviral activity of orally administered VH4004280 and VH4011499 monotherapy over 10 days in human immunodeficiency virus (HIV-1) infected Treatment-Naïve (TN) participants.
- Trial name
- CINNAMON (NCT06039579)
- Testing
- VH4004280, VH4011499, Antiretroviral therapy
- Where
- 20 sites in United States, Argentina and 7 more
- Volunteers
- 44 people
- Sponsor
- ViiV Healthcare
Chronic Hepatitis C, Medication Reaction
The Efficacy of Vosevi in Treating DAA-experienced Patients
Hepatitis C virus (HCV) infection remains a significant health problem in our country. The World Health Organization estimated that 71 million people worldwide had chronic HCV infection in 2015.
- Trial name
- NCT06180590
- Testing
- Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University